Ireland: Drugs Helsinn Invests 7 Million Dollar Investment in Helsinn Birex Pharmaceuticals
The firm is geared up to produce high quality products in line with global regulatory requirements.
Lugano/Switzerland – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, has recently announced a 7 million dollar investment at its drug product supply centre, Helsinn Birex Pharmaceuticals (HBP) in Dublin Ireland, as part of its ongoing commitment to ensuring high quality products, safeguarding its supply chain and in compliance with regulatory requirements worldwide.
Unauthorized distribution of adulterated or counterfeit products is high on the global regulatory agenda, and protecting the quality of its products during distribution is a key priority for Helsinn and its partners. The investment is designed to safeguard Helsinn’s supply of quality products that comply with stringent quality standards, and that are safe for patient use.
The investments provide HBP with the capability to apply unique serial numbers and tamper evidence features, which meet requirements of the US Drug Quality and Security Act (DQSA), the EU Falsified Medicines Directive (FMD), and other relevant local requirements in markets where Helsinn cancer care products are sold.
The enhancements to products across all markets in which Helsinn is active demonstrates the firm’s clear commitment to comply with regulatory requirements while providing partners and the patients who use the products with the assurance that the products supplied are authentic and fit for purpose.